Avtor/Urednik		Šebeštjen, M; Žegura, B; Keber, I
Naslov		Both cerivastatin and fenofibrate improve arterial vasoreactivity in patients with combined hyperlipidaemia
Tip		članek
Vir		J Intern Med
Vol. in št.		Letnik 251, št. 1
Leto izdaje		2002
Obseg		str. 77-85
Jezik		eng
Abstrakt		Objectives. The aim of this study was to compare the effects of cerivastatin and fenofibrate on endothelium dependent and independent arterial dilation. Design. In a prospective, double blind study, 38 overweight, nonsmoking, males aged between 40 and 60 years with combined hyperlipidaemia were randomized and, after 6 weeks run-in phase with American Heart Association step I diet treatment, submitted to 12 weeks treatment either with fenofibrate (250 mg daily) or cerivastatin. Cerivastatin was given in a daily dose of 0.2 mg for 6 weeks and was increased to 0.4 mg daily, if the LDL-C did not decrease below 3.0 mmol L-1. Flow-mediated (endothelium-dependent) dilation (FMD) and nitroglycerin-induced (endotheliumindependent) (gliceryltrinitrate (GTN)) dilation of brachial artery were measured using high resolution ultrasound. Results. The FMD increased from 3.4 +- 3.3 to 9.3 +- 2.4% (P < 0.001) in the cerivastatin group. and from 3.3 +- 2.8 to 6. 5 +- 3.1 % (P < 0.001) in the fenofibrate group, the improvement being significantly better after cerivastatin (P = 0.006). GTN increased from 11.5 +- 4.1 to 16.2 t 3.5% (P < 0.01) and from 11.1 +- 2.5 to 16.0 +- 2.9% (P < 0.01), respectively, with no difference between the groups. Cerivastatin reduced total cholesterol by 24%, . LDL-cholesterol by 31%. triglycerides by 24%, ox-LDL by 29% and increased HDL-cholesterol by 5%, whilst, after fenofibrate, these changes were -15, -13, -41, -17 and 18%, respectively. Only the decrease of LDL-C turned out to be an independent predictor the FMD improvement. The improvement in GTN-induced dilation did not correlate with the changes in blood lipids. (Abstract truncated at 2000 characters).
Deskriptorji		HYPERLIPIDEMIA ANTILIPEMIC AGENTS HYDROXYMETHYLGLUTARYL COA REDUCTASES PROCETOFEN PYRIDINES ADULT MIDDLE AGE BRACHIAL ARTERY DOUBLE-BLIND METHOD HEMODYNAMICS PROSPECTIVE STUDIES VASODILATION STATISTICS, NONPARAMETRIC TREATMENT OUTCOME